Rigel Pharmaceuticals Inc (RIGL) FinancialsRIGLRigel Pharmaceuticals Inc

Evaluating the bottom line, Rigel Pharmaceuticals, Inc. maintains a gross margin of 89.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 29.95%, while the net margin is 21.97%. These profitability ratios, combined with a Return on Equity (ROE) of 126.90%, provide a clear picture of how effectively RIGL converts its operational activities into shareholder value.

In the context of the broader market, RIGL competes directly with industry leaders such as SLBT and AKTS. With a market capitalization of $858.71M, it holds a significant position in the sector. When comparing efficiency, RIGL's gross margin of 89.17% stands against SLBT's N/A and AKTS's 100.00%. Such benchmarking helps identify whether Rigel Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Rigel has demonstrated strong financial performance with a gross profit margin of 89.17% in Q2 2026 and a significant increase in total revenues to $78.7 million, driven by strong sales in oncology and hematology.